Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Great Emphasis is Put on Research.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Research and Found Your Company in Austria

    29.01.2020 / 16:30 - 18:00, Zurich, Switzerland

  • New Year's Reception

    29.01.2020 / 18:00, Zurich, Switzerland

Austria Map

Find the perfect location for your company

A country like Austria considered to be an especially good terrain for upscale industrial segments, and with a particular emphasis on research and environmental friendliness, represents a major opportunity for SIAD. Our corporate goal is namely to assist the customer and provide support in improving the productivity and the environmental compatibility of its work processes.

SIAD

SIAD
More testimonials

news from the business location Austria

Turbocharger for the business location

The new Austrian Federal Government is committed to strengthening the economy, as shown in its programme, and has incorporated numerous measures to enhance the viability of Austria as a business location.

The new research allowance in Germany – in competition with the Austrian research tax credit?

Companies carrying out research and development in Austria have the possibility to apply for research funding, namely the so-called research tax credit. In an international comparison, the Austrian research tax credit is a recipe for success and is designed to showcase and enhance the attractiveness of Austria as a research location. The successive increase in the research tax credit from the original level of three percent in 2002 to 14 percent at present has made a massive contribution to this success.

More news All blog posts